Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex
- PMID: 1987452
Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex
Abstract
The triazoloquinazoline CGS 15943 is the first reported nonxanthine adenosine antagonist that has high affinity for brain adenosine receptors. In the present study, the binding of [3H] CGS 15943 to recognition sites in rat cortical membranes was characterized. Saturation experiments revealed that [3H]CGS 15943 labeled a single class of recognition sites with high affinity (Kd = 4 nM) and limited capacity (Bmax = 1.5 pmol/mg of protein). Competition studies revealed that the binding of [3H]CGS 15943 was consistent with the labeling of brain adenosine A1 receptors. Adenosine agonists inhibited 1 nM [3H]CGS 15943 binding with the following order of activity N6-cyclopentyladenosine (IC50 = 15 nM) greater than 2-chloroadenosine greater than (R)-N6-phenylisopropyladenosine greater than 5'-N6-ethylcarboxamidoadenosine greater than (S)N6-phenylisopropyladenosine greater than CGS 21680 greater than CV 1808 (IC50 greater than 10,000 nM). The potency order for adenosine antagonists was CGS 15943 (IC50 = 5 nM) greater than 8-phenyltheophylline greater than 1,3-dipropyl-8-(4-amino-2-chloro)phenylxanthine greater than 1,3-diethyl-8-phenylxanthine greater than theophylline = caffeine (IC50 greater than 10,000 nM). Antagonist inhibition curves were steep and best described by a one-site binding model. In contrast, adenosine A1 agonist competition curves were shallow, as indicated by Hill coefficients less than unity. Computer analysis revealed that these inhibition curves were best described by a two-site binding model. Agonist competition curves generated in the presence of 1 mM GTP resulted in a rightward shift and steepening of the inhibition-concentration curves, whereas antagonist binding was not altered in the presence of GTP. The complex binding interactions found with adenosine agonists indicate that [3H]CGS 15943 labels both high and low affinity components of the adenosine A1 receptor in the rat cortex. Additionally, the present data also provide some evidence that [3H]CGS 15943 may also recognize an additional low affinity binding component, which may represent a putative low affinity A2b receptor in this tissue.
Similar articles
-
Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.Br J Pharmacol. 1996 Apr;117(7):1381-6. doi: 10.1111/j.1476-5381.1996.tb15296.x. Br J Pharmacol. 1996. PMID: 8730729 Free PMC article.
-
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.J Pharmacol Exp Ther. 1989 Dec;251(3):888-93. J Pharmacol Exp Ther. 1989. PMID: 2600819
-
Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors.Naunyn Schmiedebergs Arch Pharmacol. 1996 Feb;353(3):261-71. doi: 10.1007/BF00168627. Naunyn Schmiedebergs Arch Pharmacol. 1996. PMID: 8692280
-
Characterization of adenosine A1 receptors in intact DDT1 MF-2 smooth muscle cells.Mol Pharmacol. 1990 Nov;38(5):660-6. Mol Pharmacol. 1990. PMID: 2172773
-
A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex.Br J Pharmacol. 1994 Dec;113(4):1501-7. doi: 10.1111/j.1476-5381.1994.tb17166.x. Br J Pharmacol. 1994. PMID: 7889308 Free PMC article.
Cited by
-
Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.Br J Pharmacol. 1996 Apr;117(7):1381-6. doi: 10.1111/j.1476-5381.1996.tb15296.x. Br J Pharmacol. 1996. PMID: 8730729 Free PMC article.
-
Ischaemia/reperfusion selectively attenuates coronary vasodilatation to an adenosine A2- but not to an A1-agonist in the dog.Br J Pharmacol. 1994 Apr;111(4):1233-9. doi: 10.1111/j.1476-5381.1994.tb14877.x. Br J Pharmacol. 1994. PMID: 8032610 Free PMC article.
-
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.J Med Chem. 1996 Oct 11;39(21):4142-8. doi: 10.1021/jm960482i. J Med Chem. 1996. PMID: 8863790 Free PMC article.
-
Vasodepressor Effects of Adenosine in the Cat are Independent of Cyclooxygenase, Potassium Channels, and Nitric Oxide Pathways.Drugs R D. 2019 Dec;19(4):319-328. doi: 10.1007/s40268-019-00283-2. Drugs R D. 2019. PMID: 31452117 Free PMC article.